Literature DB >> 10474473

The pathogenesis of local recurrence of melanoma at the primary excision site.

P J Heenan1, M Ghaznawie.   

Abstract

Local recurrence of melanoma at the primary excision site may imply that the primary excision was incomplete or 'inadequate', and that the recurrence was due to retained primary melanoma cells or occult microsatellites in the adjacent tissue. Pathologists frequently report these tumours in the scar as recurrent or residual melanoma, without further qualification, apparently without considering the possibility that they may be metastases and manifestations of systemic disease. In this study, 17 of 19 cases of locally recurrent melanoma at the primary excision site showed the histological features of metastasis rather than residual incompletely excised primary melanoma. Because the prevention of local recurrence is the main reason given in recommendations for wide excision of melanoma beyond complete excision of the primary tumour itself, it is essential that surgeons and pathologists should classify these neoplasms precisely as either persistent incompletely excised primary melanoma or metastatic melanoma.

Entities:  

Mesh:

Year:  1999        PMID: 10474473     DOI: 10.1054/bjps.1998.3050

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  10 in total

1.  Histopathologic excision margin affects local recurrence rate: Analysis of 2681 patients with melanoma < or = 2 mm thick.

Authors:  Peter J Heenan
Journal:  Ann Surg       Date:  2006-04       Impact factor: 12.969

2.  Synthesis and characterization of a novel pH-responsive drug-releasing nanocomposite hydrogel for skin cancer therapy and wound healing.

Authors:  Andrea Gonsalves; Pranjali Tambe; Duong Le; Dheeraj Thakore; Aniket S Wadajkar; Jian Yang; Kytai T Nguyen; Jyothi U Menon
Journal:  J Mater Chem B       Date:  2021-12-01       Impact factor: 6.331

Review 3.  Regional therapies for in-transit disease.

Authors:  Paul J Speicher; Claire H Meriwether; Douglas S Tyler
Journal:  Surg Oncol Clin N Am       Date:  2015-01-30       Impact factor: 3.495

4.  Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases.

Authors:  Nanda Kandamany; Peter Mahaffey
Journal:  Lasers Med Sci       Date:  2008-06-20       Impact factor: 3.161

5.  Differentiation of cutaneous melanoma from surrounding skin using laser-induced breakdown spectroscopy.

Authors:  Jung Hyun Han; Youngmin Moon; Jong Jin Lee; Sujeong Choi; Yong-Chul Kim; Sungho Jeong
Journal:  Biomed Opt Express       Date:  2015-12-08       Impact factor: 3.732

6.  Distribution and significance of occult intraepidermal tumor cells surrounding primary melanoma.

Authors:  Jeffrey P North; Toshiro Kageshita; Daniel Pinkel; Philip E LeBoit; Boris C Bastian
Journal:  J Invest Dermatol       Date:  2008-03-06       Impact factor: 8.551

7.  Multiple Thick Nodular Melanoma: Differentiating Multiple Primaries from the Metastasis of a Previous Single Melanoma

Authors:  Albert Alhatem; W. Clark Lambert; Robert A. Schwartz; Ravi J. Chokshi
Journal:  Balkan Med J       Date:  2019-08-26       Impact factor: 2.021

Review 8.  Surgery and radiotherapy in the treatment of cutaneous melanoma.

Authors:  A Testori; P Rutkowski; J Marsden; L Bastholt; V Chiarion-Sileni; A Hauschild; A M M Eggermont
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

9.  Surgery of primary melanomas.

Authors:  Piotr Rutkowski; Marcin Zdzienicki; Zbigniew I Nowecki; Alexander C J Van Akkooi
Journal:  Cancers (Basel)       Date:  2010-05-11       Impact factor: 6.639

10.  Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6.

Authors:  Elena De Vita; Niels Smits; Helma van den Hurk; Elizabeth M Beck; Joanne Hewitt; Gemma Baillie; Emily Russell; Andrew Pannifer; Véronique Hamon; Angus Morrison; Stuart P McElroy; Philip Jones; Natalia A Ignatenko; Nikolas Gunkel; Aubry K Miller
Journal:  ChemMedChem       Date:  2019-11-18       Impact factor: 3.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.